JAMA network open
Roxadustat Treatment After PCI Among Patients With ST-Segment Elevation Myocardial Infarction: A Randomized Clinical Trial
By Quan W, Wang Y, Zhang M and 14 others.
Abstract
Importance: Preclinical studies suggest that stabilization of hypoxia-inducible factor (HIF) may attenuate reperfusion injury.
Objective
To determine whether oral roxadustat, a HIF-prolyl hydroxylase inhibitor, reduced infarct size when administered after reperfusion among patients with ST-segment elevation myocardial infarction (STEMI). Design, setting, and participants: This phase 2, open-label, randomized clinical trial-Effect of Roxadustat in Acute Myocardial Infarction (ROXAMI)-enrolled adults with STEMI undergoing primary percutaneous coronary intervention (PCI) at a single tertiary medical center between April 1, 2021, and March 31, 2024, with follow-up through 1 year.
